Volume 112, Issue 1 pp. 39-44

Expression of cyclin A in Merkel cell carcinoma

VIRVE KOLJONEN

Corresponding Author

VIRVE KOLJONEN

Department of Plastic Surgery, Helsinki University Hospital, Helsinki, Finland; Department of

Virve Koljonen, Department of Plastic Surgery, Töölö Hospital, PO Box 266, FIN 00029 HUS, Helsinki, Finland. e-mail: [email protected]Search for more papers by this author
ERKKI TUKIAINEN

ERKKI TUKIAINEN

Department of Plastic Surgery, Helsinki University Hospital, Helsinki, Finland; Department of

Search for more papers by this author
CAJ HAGLUND

CAJ HAGLUND

Gastroenterological and General Surgery, Helsinki University Hospital, Helsinki, Finland; Department of

Search for more papers by this author
TOM BÖHLING

TOM BÖHLING

Pathology, Helsinki University and Helsinki University Hospital, Helsinki, Finland

Search for more papers by this author
First published: 12 February 2004
Citations: 7

Abstract

Merkel cell carcinoma (MCC) is a rare and aggressive primary neuroendocrine carcinoma of the skin. Large tumours, in particular, show rapid progression and metastatic dissemination, while smaller tumours show less aggressive behaviour. Cyclin A is considered to play a central role in cell cycle control. Its overexpression has been found to correlate with prognosis in many types of carcinomas and sarcomas. Twenty-six MCC patients with complete clinical data were selected. Formalin-fixed paraffin-embedded primary tumour samples were immunohistochemically stained for cyclin A. Correlation between expression of cyclin A and primary tumour size, invasion of subcutaneous tissue, local recurrence, metastasis and survival was statistically analysed. Twenty-five samples expressed cyclin A, and the mean value of positive cells was 25%. Our findings demonstrate that even small and superficial MCC show overexpression of cyclin A. There was no statistical correlation between cyclin A expression and the above-mentioned variables. Cyclin A does not seem to be useful as a prognostic tool. Consequently, size of the primary tumour (≥2 cm) remains the primary prognostic tool. As a result every tumour, even those small in size, should be considered aggressive and treated radically and rapidly.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.